CLLS Earnings Date: Nov 13, 2026 (Estimated) — Cellectis S.A.
NASDAQ · Healthcare · Biotechnology
Updated
When is CLLS's next earnings date?
Cellectis S.A. (CLLS) is expected to report Q3 2026 earnings on Friday, November 13, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.18 on revenue of $15.6M.
How did CLLS do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Cellectis S.A. posted EPS of -$0.19 versus the -$0.26 estimate, a beat of 26.9%. Revenue was $6.9M against a $11.0M estimate. The stock's 1-day post-earnings move was +5.4%.
How much does CLLS stock move after earnings?
CLLS beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.6% (up or down) in the day after earnings.
About Cellectis S.A.
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.26 | -0.19 | +26.92% | $6.9M | ✅ Beat | +5.39% | +18.22% | +20.45% |
| 2026-05-11 | Q1 2026 | -0.26 | -0.16 | +38.46% | $7.5M | ✅ Beat | -0.50% | -3.27% | -20.10% |
| 2026-03-19 | Q4 2025 | -0.10 | -0.24 | -140.00% | $12.2M | ❌ Miss | -4.02% | -8.33% | +17.82% |
| 2025-11-07 | Q3 2025 | -0.10 | 0.02 | +120.00% | $37.2M | ✅ Beat | +11.29% | +22.26% | +43.89% |
| 2025-03-13 | Q4 2024 | -0.21 | -0.16 | +23.81% | $33.2M | ✅ Beat | -3.88% | -1.55% | +11.63% |
| 2024-11-04 | Q3 2024 | -0.21 | -0.22 | -4.76% | $18.1M | ❌ Miss | +1.14% | +8.52% | +7.39% |
| 2024-08-06 | Q2 2024 | -0.30 | -0.27 | +10.00% | $9.5M | ✅ Beat | -0.48% | -0.48% | +9.66% |
| 2024-05-28 | Q1 2024 | -0.33 | -0.14 | +57.58% | $6.5M | ✅ Beat | -2.16% | -7.55% | -33.09% |
Showing last 8 quarters.